Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Rubinstein

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Cancer Chemotherapy and Pharmacology|December 22, 2025
A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumorsAlice P Chen, Shivaani Kummar, Larry Rubinstein, et al.
Oncotarget|November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.
Neuro-Oncology Practice|July 19, 2021
Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiativeLinda Dirven, Maartje E Vos, Tobias Walbert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
Neuro-Oncology|April 28, 2025
Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiativeOgechukwu A Asogwa, Linda Dirven, Tobias Walbert, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Cancer Chemotherapy and Pharmacology|December 22, 2025
A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumorsAlice P Chen, Shivaani Kummar, Larry Rubinstein, et al.
Oncotarget|November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.
Neuro-Oncology Practice|July 19, 2021
Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiativeLinda Dirven, Maartje E Vos, Tobias Walbert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
Neuro-Oncology|April 28, 2025
Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiativeOgechukwu A Asogwa, Linda Dirven, Tobias Walbert, et al.
Pageof 6